Drugs / MR308
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03062644 Comparator | Apr 2017 → Jun 2018 | — | Mundipharma Research GmbH & Co KG | Completed | Missed primary |
| Phase 3 | NCT02982161 Comparator | Dec 2016 → Jan 2018 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02982161 ↗ |
| Known as | CTC | “BACKGROUND: STARDOM2 is a randomized, double-blind, phase 3 trial evaluating the efficacy and safety of co-crystal of tramadol-celecoxib (CTC)-a first-in-class analgesic...” PMID 35974668 ↗ Sep 2022 |
| Modality | Other / unclassified | “Co-crystal of tramadol-celecoxib (CTC)” PMID 39316284 ↗ Sep 2024 |
| Route | Oral | “Mode of administration: oral” NCT02982161 ↗ |